A Study Investigating the Effectiveness of a LifeSeasons NeuroQ Supplement With Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive Decline

Exclusion Criteria

• •1. Women who are pregnant, breast feeding, or planning to become pregnant during the trial
• •2. Allergy, sensitivity, or intolerance to the investigational product's (IP) active or inactive ingredients
• •3. Self-reported confirmation of neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation. For e.g.:
• •• Schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia
• •4. Participants with vitamin deficiencies affecting cognition:
• •* Magnesium
• •* Cobalamin (Vitamin B12)
• •* Folate below the normal clinical ranges, as assessed by the QI
• •5. Participants who test below the 24th percentile or above the 75th percentile in all domains in the NCI.
• •6. Current use of prescribed medications listed in Section 8.3.1.
• •7. Current use of over-the-counter medications, supplements, foods and/or drinks listed as concomitant medications.
• •8. Unstable metabolic disease or chronic diseases as assessed by the QI
• •9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
• •10. Type II diabetes. Treatment on a stable dose of medication may be considered by the QI on a case by case basis
• •11. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case by case basis
• •12. Major surgery in the past 3 months or individuals who have planned surgery during the course of the trial. Participants with minor surgery will be considered on a case-by-case basis by the QI
• •13. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
• •14. Individuals who are immune-compromised
• •15. Verbal confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis
• •16. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones symptom free for 6 months
• •17. Verbal confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
• •18. Current or history of any significant diseases of the gastrointestinal tract
• •19. Verbal confirmation of blood/bleeding disorders
• •20. Self-reported chronic use of cannabinoid products or currently taking medical cannabinoid products containing \>0.3% tetrahydrocannabinol
• •21. Alcohol or drug abuse within the last 12 months
• •22. High alcohol intake (\>2 drinks per day or \>10 standard drinks per week)
• •23. Blood donation 30 days prior to screening, during the study, or a planned donation within 30-days of the last study visit
• •24. Participation in other clinical research trials 30 days prior to screening
• •25. Individuals who are unable to give informed consent
• •26. Any other active or unstable medical condition, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant